Form 4 REGENERON PHARMACEUTICAL For: Aug 01 Filed by: McCourt Marion

Go back to Form 4 REGENERON PHARMACEUTICAL For: Aug 01 Filed by: McCourt Marion

Oppenheimer Positive on Regeneron Pharma (REGN), 'We anticipate material pipeline readouts in 2H22/1H23'

August 4, 2022 10:21 AM EDT

Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $775.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Regeneron (REGN) reported 2Q22 sales/earnings on 8/3 and provided a business update. Sales modestly outpaced OPCO expectations while earnings beat our estimates by... More